Perthera Clinical and Scientific Results

Perthera is honored to have been accepted to present at numerous conferences and symposiums throughout the years.

Perthera AI, Perthera’s Artificial Intelligence system, integrates the patient’s multi-omic cell architecture and treatment history with our leading-edge Therapeutic Intelligence Engine; the output is assessed and approved by our every-patient, real-time physician, and scientific tumor board.

The collective data from Perthera Precision Medicine along with our patient outcomes data provides for statistically significant findings for research and publication.

Preliminary Observations of Blood-based Molecular Testing in a Subset of Patients
with Pancreatic Cancer Participating in the Know Your Tumor (KYT) Initiative
  • Based on this pilot study, given that BB-cfDNA testing could not identify known KRAS mutations in a small percentage of patients with disseminated and metastatic disease, we conclude that BBcfDNA testing is not ready for clinical decision making, especially in the arena of precision therapy for PDA.
  • Tumor tissue testing should still remain the gold standard.
  • Future studies evaluating BB-cfDNA platforms in PDA cohorts
    should consider: 1) side by side testing with TT and 2) the use of KRAS mutations as a gold standard biomarker for this disease.
  • Sequencing germline (constitutional gDNA not from the tumor) should be considered in an effort to define true somatic events.

Molecular and clinical characterization of
BRAF mutations in pancreatic ductal
adenocarcinomas (PDACs)

  • BRAF mutations are significantly and inversely correlated with KRAS alterations
  • The most common BRAF alteration, V600E mutation, was
    found to be mutually exclusive with the KRAS mutation
  • Clinical trials targeting BRAF alterations in KRAS wildtype
    pancreatic cancer appears warranted

Multi-omic Molecular Comparison of Primary Versus Metastatic Pancreatic Tumors

  • The comparison of the molecular characteristics of
    primary vs metastatic pancreatic adenocarcinoma in
    patients who have received Perthera Reports
    reveals that the molecular characteristics are very
    similar and that actionable alterations are identified
    at the same frequency.
  • Our findings support the belief that primary
    pancreatic cancers metastasize very early and thus:
  • The role of biomarker-directed therapy for early-stage
    pancreatic cancers in lieu of, or in
    addition to standard therapy could be further
    evaluated in prospective clinical trials.
  • In addition, re-biopsy at recurrence may not be
    necessary which can decrease patient
    discomfort and anxiety, cost, and delay to next
    treatment.cial.
A Computational Model for Integrating
Genomic Data with Public Datasets
For Molecular Tumor Board Recommendations
  • The method presented here can be useful in summarizing the available evidence linking mutations with drug response, and in prioritizing multiple, sometimes conflicting, biomarkers:
    • Hypothesis generation for in vitro validation
    • Interpretation of the impact of molecular profiles on observed differences in drug response across patient populations
  • Computational challenges related to scale-up of this approach:
    • Parameter estimation against cell line and other experimental data2,3
    • Simulation of networks with cycles (feedback loops)4
  • As outcomes data are collected for Perthera patients, molecular profiles of patients will be simulated to suggest potential mechanism for observed response/lack of response to targeted therapies